Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-07-04
2006-07-04
Kemmerer, Elizabeth (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S368000, C435S372000, C435S810000, C435S975000, C530S387100, C530S388100, C530S388260
Reexamination Certificate
active
07070945
ABSTRACT:
A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed.
REFERENCES:
patent: 5445937 (1995-08-01), Haley
patent: 5508167 (1996-04-01), Roses et al.
patent: 6451547 (2002-09-01), Jackowski et al.
Takahashi et al. Immunoassay for serum glutamine synthetase in serum: development, reference values, and preliminary study in dementias. Clin Chem 48(2): 375-378, 2002.
Luis et al. Mild cognitive impairment. Neurology 61: 438-444, 2003.
Tumani et al., Glutamine synthetase in cerebrospinal fluid, serum, and brain, Arch. Neurol., (1999) 56, pp 1241-1246.
Gunnersen et al., Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: A potential diagnostic biochemical marker, Proc. Natl. Acad.Sci., (1992) 89, pp 11949-11953.
Hensley et al., A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease, Pro. Natl. Acad.Sci., (1994) 91, pp 3270-3274.
Sheng et al., S100β protein expression in Alzheimer disease: Potential role in the phatogensis of neuritic plaques, J. of Neurosci. Res., (1994) pp 398-404.
Mrak et al., Correlation of astrocytic S100β expression with dystrophic neurites in amyloid plaques of Alzheimer's disease, J. of Neuropathol. and Exp. Neurol., (1996) 55, 3, pp 273-279.
Tumani et al., Purification and immunocharacterization of human brain glutamine synthetase and its detection in cerebrospinal fluid and serum by a sandwich enzyme immunoassay, J. of Immunol. Meth., (1995) 188, pp 155-163.
Boksha et al., “Glutamine Synthetase and Glutamine Synthetase-Like Protein from Human Brain: Purification and Comparative Characterization”, Journal of Neurochemistry, vol. 75, No. 6, (2000), pp. 2574-2582.
Jackowski George
Takahashi Miyoko
Bunner Bridget E.
Kemmerer Elizabeth
McHale & Slavin P.A.
Syn X Pharma, Inc.
LandOfFree
Process for determining the presence of monomeric brain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for determining the presence of monomeric brain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for determining the presence of monomeric brain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3558129